Loading
HKSEHealthcareMedical - Distribution
Latest quote
HK$0.145
HK$0.00 · 0.00%
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its product portfolio includes Octapharma, a human albumin solution specifically for premature infants; Axetine, prescribed for a range of bacterial infections such as respiratory, urinary tract, soft tissue, gynecological, obstetrical, and gonorrheal infections, and for post-surgical infection prevention; and Medocef, used to treat bacterial infections affecting the lower respiratory tract (including pneumonia), urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and conditions like sepsis. The company also supplies Esafosfina, effective in managing hypophosphatemia and chronic ailments like alcohol intoxication, malnutrition, and respiratory failure due to low phosphate levels. Additionally, it offers Taurolite, a third-generation oral cholic acid drug for gallstone diseases, and Tamifil injection, indicated for metastatic prostate cancer, true precocious puberty, and endometriosis. Beyond these core services, Sinco Pharmaceuticals also conducts sales of medicinal products, operates warehousing facilities for pharmaceuticals, provides international trade services, and offers consultation in medical and biological technology. Established in 2011, the company's headquarters are situated in Chengdu, People's Republic of China, and it operates as a subsidiary of Risun Investments Limited.
Latest quote
HK$0.145
HK$0.00 · 0.00%
Regular session · HKT · Market data may be delayed.
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its product portfolio includes Octapharma, a human albumin solution specifically for premature infants; Axetine, prescribed for a range of bacterial infections such as respiratory, urinary tract, soft tissue, gynecological, obstetrical, and gonorrheal infections, and for post-surgical infection prevention; and Medocef, used to treat bacterial infections affecting the lower respiratory tract (including pneumonia), urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and conditions like sepsis. The company also supplies Esafosfina, effective in managing hypophosphatemia and chronic ailments like alcohol intoxication, malnutrition, and respiratory failure due to low phosphate levels. Additionally, it offers Taurolite, a third-generation oral cholic acid drug for gallstone diseases, and Tamifil injection, indicated for metastatic prostate cancer, true precocious puberty, and endometriosis. Beyond these core services, Sinco Pharmaceuticals also conducts sales of medicinal products, operates warehousing facilities for pharmaceuticals, provides international trade services, and offers consultation in medical and biological technology. Established in 2011, the company's headquarters are situated in Chengdu, People's Republic of China, and it operates as a subsidiary of Risun Investments Limited.
52-week range
Current HK$0.145
Regular session · HKT · Market data may be delayed.
Sinco Pharmaceuticals Holdings Limited operates as an investment holding entity primarily specializing in the marketing, promotion, and distribution channel management of imported pharmaceutical products and medical devices throughout China. Its product portfolio includes Octapharma, a human albumin solution specifically for premature infants; Axetine, prescribed for a range of bacterial infections such as respiratory, urinary tract, soft tissue, gynecological, obstetrical, and gonorrheal infections, and for post-surgical infection prevention; and Medocef, used to treat bacterial infections affecting the lower respiratory tract (including pneumonia), urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and conditions like sepsis. The company also supplies Esafosfina, effective in managing hypophosphatemia and chronic ailments like alcohol intoxication, malnutrition, and respiratory failure due to low phosphate levels. Additionally, it offers Taurolite, a third-generation oral cholic acid drug for gallstone diseases, and Tamifil injection, indicated for metastatic prostate cancer, true precocious puberty, and endometriosis. Beyond these core services, Sinco Pharmaceuticals also conducts sales of medicinal products, operates warehousing facilities for pharmaceuticals, provides international trade services, and offers consultation in medical and biological technology. Established in 2011, the company's headquarters are situated in Chengdu, People's Republic of China, and it operates as a subsidiary of Risun Investments Limited.
52-week range
Current HK$0.145
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.08B CNY | 2.82B CNY | 2.54B CNY | 2.27B CNY | 2.02B CNY |
| Cost of goods sold | 1.86B CNY | 2.52B CNY | 2.22B CNY | 1.97B CNY | 1.66B CNY |
| Gross profit | 222.09M CNY | 299.94M CNY | 323.28M CNY | 305.87M CNY | 364.95M CNY |
| Research and development | 2.68M CNY | 19M CNY | 8.29M CNY | 11.27M CNY | 26.16M CNY |
| Selling, general, and administrative | 147.42M CNY | 189.92M CNY | 202.58M CNY | 198.44M CNY | 171.38M CNY |
| Operating expenses | 150.09M CNY | 205M CNY | 215.11M CNY | 215.91M CNY | 198.56M CNY |
| Interest income | 3.92M CNY | 6.12M CNY | 1.34M CNY | 2.42M CNY | 1.58M CNY |
| Interest expense | 33.06M CNY | 12.55M CNY | 9.81M CNY | 13.81M CNY | 27.22M CNY |
| Depreciation and amortization | 18.78M CNY | 18.66M CNY | 16.32M CNY | 7.79M CNY | 5.14M CNY |
| Operating income | 72M CNY | 94.95M CNY | 108.17M CNY | 89.95M CNY | 166.39M CNY |
| Net income | 34.85M CNY | 42.05M CNY | 42.35M CNY | 69.46M CNY | 135.08M CNY |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.002
2025 complete year-39.4% since 2016
2026 partial: HK$0.0017
HK$0.0033
2,016
HK$0.0098
2,023
HK$0.0039
2,024
HK$0.002
2,025
HK$0.0017
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 19, 2026 | HK$0.0017Annual | May 21, 2026 | Jun 4, 2026 |
Dividend | May 19, 2025 | HK$0.002Annual | May 21, 2025 | Jun 3, 2025 |
Dividend | May 20, 2024 | HK$0.0039Annual | May 21, 2024 | Jun 4, 2024 |
Dividend | May 31, 2023 | HK$0.0098Annual | Jun 1, 2023 | Jun 15, 2023 |
Dividend | Sep 9, 2016 | HK$0.0033Annual | Sep 12, 2016 | Oct 18, 2016 |
Ex-dividend May 19, 2026
HK$0.0017
Annual
Record May 21, 2026 · Payment Jun 4, 2026
Ex-dividend May 19, 2025
HK$0.002
Annual
Record May 21, 2025 · Payment Jun 3, 2025
Ex-dividend May 20, 2024
HK$0.0039
Annual
Record May 21, 2024 · Payment Jun 4, 2024
Ex-dividend May 31, 2023
HK$0.0098
Annual
Record Jun 1, 2023 · Payment Jun 15, 2023
Ex-dividend Sep 9, 2016
HK$0.0033
Annual
Record Sep 12, 2016 · Payment Oct 18, 2016
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
